Evidence map›Paper›PMID 19198616›Full record

ReviewNature reviews. Microbiology2009

The spike protein of SARS-CoV--a target for vaccine and therapeutic development.

Lanying Du, Yuxian He, Yusen Zhou, Shuwen Liu, Bo-Jian Zheng, Shibo Jiang

Registry-linked trialAbstract readReview
In one paragraph

Review in Nature reviews. Microbiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05162482 (Immunogenicity and Safety of Heterologous Combinations of COVID-19 Vaccines Available Under Emergency Use Authorization in Pakistan), which is not on this map. Cited by 991 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
991citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05162482 phase2unknown statusnot on this mapstarted 2022, after this paper: background citation

Immunogenicity and Safety of Heterologous Combinations of COVID-19 Vaccines Available Under Emergency Use Authorization in Pakistan: A Randomized Phase II Trial

TypeinterventionalSponsorAga Khan University Hospital, PakistanRan2022 to 2024Enrolled1,680ConditionsCOVID 19 VaccineArmsBIBP (CNBG, Sinopharm) WIV, CanSinoBIO, AstraZeneca ChAdOx
3 · Its place in the literature

Who cites it

991 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. SARS-CoV-2 drives upregulation of EpCAM in respiratory epithelial cells with hypercellular profile during severe COVID-19.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

931 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lanying DuLindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street, New York, NY 10065, USA.
Yuxian He
Yusen Zhou
Shuwen Liu
Bo-Jian Zheng
Shibo Jiang

Funding

SARS-CoV S Protein Receptor-binding Domain-based VaccinesR01AI068002 · NIAID · NEW YORK BLOOD CENTER · PI JIANG, SHIBO · 2007 to 2010
$1.5M
NIAID NIH HHS R01 AI068002NIAID NIH HHS R01 AI 68002
6 · The paper itself

Abstract

Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease caused by a novel coronavirus, SARS-coronavirus (SARS-CoV). The SARS-CoV spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotensin-converting enzyme 2 and the S2 subunit mediates fusion between the viral and host cell membranes. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV. In this Review, we highlight recent advances in the development of vaccines and therapeutics based on the S protein.

Indexed as

Severe acute respiratory syndrome-related coronavirusViral VaccinesAngiotensin-Converting Enzyme 2AnimalsAntibodies, MonoclonalAntiviral AgentsHumansMembrane GlycoproteinsPeptidyl-Dipeptidase ARNA InterferenceRNA, Small InterferingSevere Acute Respiratory SyndromeSpike Glycoprotein, CoronavirusViral Envelope ProteinsVirus InternalizationACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, MonoclonalAntiviral AgentsMembrane GlycoproteinsPeptidyl-Dipeptidase ARNA, Small InterferingSpike Glycoprotein, Coronavirusspike glycoprotein, SARS-CoVspike protein, mouse hepatitis virusViral Envelope ProteinsViral Vaccines

Identifiers

PMID19198616
PMCPMC2750777

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.